<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317759</url>
  </required_header>
  <id_info>
    <org_study_id>1796.00</org_study_id>
    <secondary_id>FHCRC-1796.00</secondary_id>
    <secondary_id>CDR0000327817</secondary_id>
    <nct_id>NCT00317759</nct_id>
  </id_info>
  <brief_title>Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Fludarabine Lymphodepletion for Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to&#xD;
      stimulate the immune system and stop cancer cells from growing. Fludarabine may help the&#xD;
      immune system kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of fludarabine followed by cellular&#xD;
      adoptive immunotherapy in treating patients who have metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and toxicity of adoptive immunotherapy comprising autologous CD8+&#xD;
           antigen-specific cytotoxic T-lymphocyte (CTL) clones after fludarabine in patients with&#xD;
           stage IV melanoma.&#xD;
&#xD;
        -  Determine the duration of in vivo persistence of these CTL clones in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the antitumor effect of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized study.&#xD;
&#xD;
      Patients undergo leukapheresis or weekly phlebotomy for the collection of peripheral blood&#xD;
      mononuclear cells from which autologous antigen-specific CD8+ cytotoxic T-lymphocyte (CTL)&#xD;
      clones are generated. Patients receive autologous antigen-specific CD8+ CTL clones IV over&#xD;
      30-60 minutes on days 0 and 21 in the absence of rapid disease progression or unacceptable&#xD;
      toxicity. Patients also receive fludarabine IV once daily on days 14-18.&#xD;
&#xD;
      Patients are followed for up to 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
          -  HLA-A2 or -A3-expressing disease&#xD;
&#xD;
          -  Bidimensionally measurable residual disease by palpation or radiographic imaging&#xD;
             (e.g., x-ray or CT scan)&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
               -  Previously treated CNS involvement allowed provided there is no evidence of CNS&#xD;
                  disease at least 2 months after completion of therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 2,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT no greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin no greater than 1.6 mg/dL&#xD;
&#xD;
          -  INR no greater than 1.5 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No clinically significant hypotension&#xD;
&#xD;
          -  No symptoms of coronary artery disease&#xD;
&#xD;
          -  No cardiac arrhythmia by EKG requiring drug therapy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically significant pulmonary dysfunction&#xD;
&#xD;
          -  FEV_1 at least 1.0 L*&#xD;
&#xD;
          -  DLCO at least 45%* NOTE: *For patients with a history of pulmonary dysfunction&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No oral temperature greater than 38.2Â°C within the past 48 hours&#xD;
&#xD;
          -  No systemic infection requiring chronic maintenance or suppressive therapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy (e.g., interleukins, interferons, melanoma vaccines, IV&#xD;
             immunoglobulins, expanded polyclonal tumor-infiltrating lymphocytes, or&#xD;
             lymphokine-activated killer therapy)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (standard or experimental)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior immunosuppressive therapy&#xD;
&#xD;
          -  No concurrent pentoxifylline&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassian Yee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One. 2009;4(3):e4749. doi: 10.1371/journal.pone.0004749. Epub 2009 Mar 9.</citation>
    <PMID>19270751</PMID>
  </results_reference>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>April 24, 2006</study_first_submitted>
  <study_first_submitted_qc>April 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2006</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2015</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

